BioVie to Present Alzheimer’s and Long COVID Bezisterim Data at ACP Meeting
BioVie secured presentations on two bezisterim abstracts for the American College of Psychiatrists meeting Feb 18-22, 2026, covering Alzheimer’s anti-inflammatory epigenetic modulation and baseline data from the Phase 2 Long COVID ADDRESS-LC trial. This recognition spotlights NE3107’s clinical advancement and may boost investor confidence ahead of mid-2026 topline results.
1. Presentation Details
Two bezisterim abstracts have been accepted for poster presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida, scheduled for February 18-22. Both posters will be showcased on February 18, highlighting BioVie’s progress in neurological drug development.
2. Alzheimer’s Abstract
The first abstract, titled “Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer’s Disease,” examines the drug’s impact on key neuroinflammation pathways (ERK, NFκB, TNF-α) and potential cognitive improvements in Alzheimer’s patients.
3. Long COVID Abstract
The second abstract presents baseline characteristics of participants in the Phase 2 ADDRESS-LC trial, studying bezisterim’s ability to reduce brain fog, fatigue and other neurological symptoms linked to Long COVID in an approximately 200-patient cohort.
4. Pipeline Impact and Next Steps
Acceptance at ACP underscores NE3107’s clinical momentum following positive Phase 2 Parkinson’s data. BioVie anticipates topline results for both the SUNRISE-PD and ADDRESS-LC trials by mid-2026, which could materially influence its valuation and development strategy.